Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Boehringer Ingelheim Bullish In Oncology Despite Olmutinib U-Turn

Executive Summary

Boehringer Ingelheim culled its late-stage lung cancer partnership with Hanmi after spending $65m in the first year because of the rapidly changing environment in the EGFR-positive lung cancer space. The German company doesn't intend to sit around licking its olmutinib-induced wounds, though, and is still committed to the lung cancer space.


Related Content

Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair
Boehringer Gets Option To Buy ViraTherapeutics And Cancer Virus Therapy
Clovis Pulls Plug On Rociletinib On Expected FDA Rejection
ANALYSIS: Hanmi Deal Strengthens BI’s Hand But Competitors Ahead


Related Companies